A venture syndicate led by Novo Holdings A/S, with participation from EQT Life Sciences, has raised $100 million for Asceneuron SA enabling it to advance a new product for Alzheimer’s disease. Based in Lausanne, Switzerland, Asceneuron is developing a small molecule drug, ASN51, that inhibits an enzyme implicated in the aggregation of proteins in the brain. This is thought to have application for both Alzheimer’s and Parkinson’s diseases, as well as amyotrophic lateral sclerosis.
